Schedule

Thursday, Nov. 2, 2023 | 9 a.m.–5:30 p.m. PDT

Session I: Myeloid Cells in Cancer: Recent Advances

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>9 a.m. PDT</td>
<td>Upper Level – Ballroom 6CD</td>
<td>Judith A. Varner, PhD – University of California, San Diego</td>
</tr>
<tr>
<td>9:05 a.m. PDT</td>
<td>Tumor-associated Macrophage Heterogeneity</td>
<td>Florent Ginhoux, PhD – Gustave Roussy</td>
</tr>
<tr>
<td>9:30 a.m. PDT</td>
<td>Targeting the PDAC Tumor Microenvironment to Improve Antitumor Immunity</td>
<td>David G. DeNardo, PhD – Washington University, St. Louis</td>
</tr>
<tr>
<td>9:55 a.m. PDT</td>
<td>Pre-metastatic Niche and Myeloid Cells</td>
<td>Rosandra N. Kaplan, MD – National Institutes of Health/National Cancer Institute</td>
</tr>
<tr>
<td>10:20 a.m. PDT</td>
<td>Unleashing the Antitumor Potential of Neutrophil in the Context of Immune Based Intervention</td>
<td>Taha Merghoub, PhD – Weill Cornell Medicine</td>
</tr>
<tr>
<td>10:45 a.m. PDT</td>
<td>Break</td>
<td></td>
</tr>
</tbody>
</table>

Session II: Myeloid Cell Signaling

<table>
<thead>
<tr>
<th>Time</th>
<th>Location</th>
<th>Moderator</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:55 a.m. PDT</td>
<td>Introduction/Overview</td>
<td>Dmitry I. Gabrilovich, MD, PhD – AstraZeneca</td>
</tr>
<tr>
<td>11 a.m. PDT</td>
<td>How do anti-TREM2 and anti-PD1 Treatments Work Together Synergistically?</td>
<td>Marco Colonna, MD – Washington University School of Medicine</td>
</tr>
<tr>
<td>11:25 a.m. PDT</td>
<td>PI3 Kinase Gamma and Upstream Regulators of Immune Suppression</td>
<td>Judith A. Varner, PhD – University of California, San Diego</td>
</tr>
<tr>
<td>11:50 a.m. PDT</td>
<td>Arginase 1 in Neutrophil Extracellular Traps constrains Antitumor T Cell Immunity</td>
<td>Vincenzo Bronte, MD – Veneto Institute of Oncology</td>
</tr>
<tr>
<td>12:15 p.m. PDT</td>
<td>Lunch</td>
<td></td>
</tr>
</tbody>
</table>
# Schedule

## Session III: Regulation of Myeloid Cell Metabolism in Cancer

**Time:** 1:40–3:25 p.m. PDT  
**Location:** Upper Level – Ballroom 6CD  
**San Diego Convention Center**

**Moderator:** Vincenzo Bronte, MD – *Veneto Institute of Oncology*

1:40 p.m. PDT  **Introduction/Overview**  
Vincenzo Bronte, MD – *Veneto Institute of Oncology*

1:45 p.m. PDT  **Reprogramming of Tumor-associated Immunosuppressive Myelopoiesis for the Benefit of Immunotherapy**  
Paulo C. Rodriguez, PhD – *Moffitt Cancer Center*

2:10 p.m. PDT  **Ferroptosis in Tumor Microenvironment**  
Dmitry I. Gabrilovich, MD, PhD – *AstraZeneca*

2:35 p.m. PDT  **Metabolic Switch of Immunosuppressive Myelopoiesis in Cancer**  
Antonio Sica, PhD – *University of Eastern Piedmont, Italy*

3 p.m. PDT  **Targeting Macrophage Lipid Metabolism to Enhance Anti-tumor Responses**  
Jennifer L. Guerriero, PhD – *Brigham and Women’s Hospital*

3:25 p.m. PDT  **Break**

## Session IV: Therapeutic Targeting of Myeloid Cells in Cancer

**Time:** 3:40–5:30 p.m. PDT  
**Location:** Upper Level – Ballroom 6CD  
**San Diego Convention Center**

**Moderator:** Jennifer L. Guerriero, PhD – *Brigham and Women’s Hospital*

3:40 p.m. PDT  **Introduction/Overview**  
Jennifer L. Guerriero, PhD – *Brigham and Women’s Hospital*

3:45 p.m. PDT  **Dendritic Cells**  
Ira Mellman, PhD – *Genentech*

4:10 p.m. PDT  **Enhanced Targeting of Myeloid Derived Suppressor Cells in Melanoma with ATRA and Checkpoint Inhibitors**  
Martin McCarter, MD – *University of Colorado School of Medicine*

4:35 p.m. PDT  **Develop a Novel Class of Myeloid Checkpoint Inhibitors by Targeting LILRB Family of Myeloid Inhibitory Receptors**  
Charlene Liao, PhD – *Immune-Onc Therapeutics, Inc.*

5 p.m. PDT  **Learning from the Clinic to Improve Success of Myeloid Cell Targeting Therapies**  
Simon Barry, PhD – *AstraZeneca*

5:25 p.m. PDT  **Closing Remarks**  
Jennifer L. Guerriero, PhD – *Brigham and Women’s Hospital*